Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02707107 · ClinicalTrials.gov registry record · Phase 1
MED Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous WCK 5222 (Zidebactam and Cefepime) in Healthy Volunteers
A Phase 1 study, sponsored by Wockhardt.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT02707107 is a Phase 1 study that has completed, run by Wockhardt. The registered enrollment target is 20 participants.
The verdict
NCT02707107, a Phase 1 study, has completed, sponsored by Wockhardt.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
Study to evaluate the safety, tolerability and pharmacokinetics of multiple escalating doses of intravenous WCK 5222 (Zidebactam and Cefepime) in healthy adult human subjects.
Interventions
- DRUG Placebo
- DRUG Intravenous infusions of WCK 5222
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2016-03 |
| Est. Completion | 2016-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02707107
The ClinicalTrials.gov registry entry for NCT02707107 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wockhardt, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02707107 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02707107 about?
NCT02707107 is a clinical study titled "MED Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous WCK 5222 (Zidebactam and Cefepime) in Healthy Volunteers". Study to evaluate the safety, tolerability and pharmacokinetics of multiple escalating doses of intravenous WCK 5222 (Zidebactam and Cefepime) in healthy adult human subjects.
What is the current status of trial NCT02707107?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2016-03. Estimated completion is 2016-04.
What interventions are being tested in trial NCT02707107?
The interventions under investigation include: Placebo (DRUG), Intravenous infusions of WCK 5222 (DRUG).
Who is sponsoring clinical trial NCT02707107?
This trial is sponsored by Wockhardt, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.